Search the Epitope Variant and Escape Mutation Database

Help

Found 6 matching records:

Displaying record number 57432

HXB2 Location Gag(216-224) Gag Epitope Map
View variants at this location

HPVHAGPVA

`HPVqAGPVA`		non-susceptible form; susceptible form
`HPVHAGPiA`		non-susceptible form; susceptible form
`HPVHAGPip`		non-susceptible form; susceptible form
`HPVHAGPVp`		non-susceptible form; susceptible form
`HPaHAGPVA`		non-susceptible form; susceptible form
`HPVaAGPVA`		non-susceptible form; susceptible form
`HPVHvGPVA`		non-susceptible form; susceptible form
`HPVHAaPVA`		non-susceptible form; susceptible form

Epitope Name HA9

Species (MHC/HLA) human(B7 supertype)

Variant Details

Showing all: 8 variant(s).

Variant ID.	`2472`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVqAGPVA`
Mutations	H/Q
Epitope Location	H4Q
HXB2 Location	H219Q
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVqAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2473`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVHAGPiA`
Mutations	V/I
Epitope Location	V8I
HXB2 Location	V223I
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPiA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2474`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVHAGPip`
Mutations	V/I A/P
Epitope Location	V8I A9P
HXB2 Location	V223I A224P
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPip, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2475`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVHAGPVp`
Mutations	A/P
Epitope Location	A9P
HXB2 Location	A224P
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPVp, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2476`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPaHAGPVA`
Mutations	V/A
Epitope Location	V3A
HXB2 Location	V218A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPaHAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2477`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVaAGPVA`
Mutations	H/A
Epitope Location	H4A
HXB2 Location	H219A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	D
Method	CD8 T-cell Elispot - IFNy
Note	Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVaAGPVA, but cells encountering this variant were not susceptible in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 2295 (Caucasian female, experienced some treatment, autologous virus Clade C).

Variant ID.	`2478`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVHvGPVA`
Mutations	A/V
Epitope Location	A5V
HXB2 Location	A220V
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHvGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2479`
Epitope Seq.	`HPVHAGPVA`
Variant Seq.	`HPVHAaPVA`
Mutations	G/A
Epitope Location	G6A
HXB2 Location	G221A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAaPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

References

Hoof2010 Ilka Hoof, Carina L. Pérez, Marcus Buggert, Rasmus K. L. Gustafsson, Morten Nielsen, Ole Lund, and Annika C. Karlsson. Interdisciplinary Analysis of HIV-Specific CD8+ T Cell Responses against Variant Epitopes Reveals Restricted TCR Promiscuity. J Immunol, 184(9):5383-5391, 1 May 2010. PubMed ID: 20363973. Show all entries for this paper.

Displaying record number 57493

HXB2 Location Gag(259-267) Gag Epitope Map
View variants at this location

Epitope

GEIYKRWII

Epitope Alignment

Variants

`GdIYKRWII`		susceptible form
`GEIYKRWIv`		susceptible form
`GEIYKaWII`		non-susceptible form; susceptible form
`GEIYaRWII`		non-susceptible form
`GEIaKRWII`		non-susceptible form; susceptible form
`GEIYrRWII`		susceptible form

Epitope Name GI9

Species (MHC/HLA) human

Variant Details

Showing all: 6 variant(s).

Variant ID.	`2480`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GdIYKRWII`
Mutations	E/D
Epitope Location	E2D
HXB2 Location	E260D
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GdIYKRWII.

Variant ID.	`2481`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIYKRWIv`
Mutations	I/V
Epitope Location	I9V
HXB2 Location	I267V
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYKRWIv.

Variant ID.	`2482`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIYKaWII`
Mutations	R/A
Epitope Location	R6A
HXB2 Location	R264A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIYKaWII, but patient 2902 (Caucasian male, treated, autologous virus Clade B) did not elicit a response upon encountering this variant.

Variant ID.	`2483`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIYaRWII`
Mutations	K/A
Epitope Location	K5A
HXB2 Location	K263A
Mutation Type	NSF: non-susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	All 3 patients, 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) did not elicit CTL responses to variant GEIYaRWII.

Variant ID.	`2484`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIaKRWII`
Mutations	Y/A
Epitope Location	Y4A
HXB2 Location	Y262A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Patient 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIaKRWII, but patients 2902 (Caucasian male, treated, autologous virus Clade B) and 2275 (Latin male, experienced some treatment, autologous virus Clade B)did not elicit a response upon encountering this variant.

Variant ID.	`2485`
Epitope Seq.	`GEIYKRWII`
Variant Seq.	`GEIYrRWII`
Mutations	K/R
Epitope Location	K5R
HXB2 Location	K263R
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYrRWII.

References

Displaying record number 57497

HXB2 Location Pol(311-319) Pol Epitope Map
View variants at this location

Epitope

SPAIFQSSM

Epitope Alignment

Variants

`SPsIFQSSM`		susceptible form
`SPAIFQcSM`		susceptible form
`SPAIFQaSM`		susceptible form
`SPsIFQcSM`		non-susceptible form; susceptible form
`SPAIFaSSM`		non-susceptible form; susceptible form
`SPAaFQSSM`		non-susceptible form
`SPAIaQSSM`		non-susceptible form

Epitope Name SM9

Species (MHC/HLA) human

Variant Details

Showing all: 7 variant(s).

Variant ID.	`2497`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPsIFQSSM`
Mutations	A/S
Epitope Location	A3S
HXB2 Location	A313S
Mutation Type	SF: susceptible form
Epitope Subtype	A1, B
Variant Subtype	A1
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant, SPsIFQSSM, continued to elicit a response in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

Variant ID.	`2498`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPAIFQcSM`
Mutations	S/C
Epitope Location	S7C
HXB2 Location	S317C
Mutation Type	SF: susceptible form
Epitope Subtype	A1, B
Variant Subtype	A1, B
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant SPAIFQcSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

Variant ID.	`2499`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPAIFQaSM`
Mutations	S/A
Epitope Location	S7A
HXB2 Location	S317A
Mutation Type	SF: susceptible form
Epitope Subtype	A1, B
Variant Subtype	A1, B
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant SPAIFQaSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

Variant ID.	`2500`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPsIFQcSM`
Mutations	A/S S/C
Epitope Location	A3S S7C
HXB2 Location	A313S S317C
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B
Variant Subtype	A1, B
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant SPsIFQcSM continued to elicit CTL response in patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1). No CTL response was seen in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).

Variant ID.	`2501`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPAIFaSSM`
Mutations	Q/A
Epitope Location	Q6A
HXB2 Location	Q316A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B
Variant Subtype	A1
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant SPAIFaSSM continued to elicit CTL response though at a low level, in patient 2632 (African female, experienced some treatment, autologous virus Clade A1). CTL from patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1) did not respond to this variant.

Variant ID.	`2502`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPAaFQSSM`
Mutations	I/A
Epitope Location	I4A
HXB2 Location	I314A
Mutation Type	NSF: non-susceptible form
Epitope Subtype	A1, B
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant, SPAaFQSSM did not elicit a response in any patients - 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

Variant ID.	`2503`
Epitope Seq.	`SPAIFQSSM`
Variant Seq.	`SPAIaQSSM`
Mutations	F/A
Epitope Location	F5A
HXB2 Location	F315A
Mutation Type	NSF: non-susceptible form
Epitope Subtype	A1, B
Method	CD8 T-cell Elispot - IFNy
Note	SM9 variant, SPAIaQSSM did not elicit a response in any patients - 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).

References

Displaying record number 57494

HXB2 Location Nef(73-81) Nef Epitope Map
View variants at this location

Epitope

QVPLRPMTY

Epitope Alignment

Variants

`QVPvRPMTY`		susceptible form
`QaPLRPMTY`		non-susceptible form; susceptible form
`QVPLRPMTf`		non-susceptible form; susceptible form
`QVPaRPMTY`		non-susceptible form; susceptible form
`QVPLRaMTY`		non-susceptible form; susceptible form
`QVPLaPMTY`		non-susceptible form; susceptible form

Epitope Name QY9

Species (MHC/HLA) human

Variant Details

Showing all: 6 variant(s).

Variant ID.	`2486`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QVPvRPMTY`
Mutations	L/V
Epitope Location	L4V
HXB2 Location	L76V
Mutation Type	SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPvRPMTY.

Variant ID.	`2487`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QaPLRPMTY`
Mutations	V/A
Epitope Location	V2A
HXB2 Location	V74A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QaPLRPMTY, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

Variant ID.	`2488`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QVPLRPMTf`
Mutations	Y/F
Epitope Location	Y9F
HXB2 Location	Y81F
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	C, D
Method	CD8 T-cell Elispot - IFNy
Note	Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPLRPMTf, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

Variant ID.	`2489`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QVPaRPMTY`
Mutations	L/A
Epitope Location	L4A
HXB2 Location	L76A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	D
Method	CD8 T-cell Elispot - IFNy
Note	Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPaRPMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

Variant ID.	`2491`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QVPLRaMTY`
Mutations	P/A
Epitope Location	P6A
HXB2 Location	P78A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	D
Method	CD8 T-cell Elispot - IFNy
Note	Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPLRaMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

Variant ID.	`2492`
Epitope Seq.	`QVPLRPMTY`
Variant Seq.	`QVPLaPMTY`
Mutations	R/A
Epitope Location	R5A
HXB2 Location	R77A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	B, C, D
Variant Subtype	C
Method	CD8 T-cell Elispot - IFNy
Note	Patient 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) continued to elicit CTL response to variant QVPLaPMTY, but CTL from patients 2840 (African female, treated, autologous virus Clade D); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.

References

Displaying record number 57495

HXB2 Location Nef(84-92) Nef Epitope Map
View variants at this location

Epitope

AVDLSHFLK

Epitope Alignment

Variants

`AlDLSHFLK`		non-susceptible form; susceptible form
`AVDLgHFLK`		non-susceptible form; susceptible form
`AVDLaHFLK`		non-susceptible form; susceptible form
`AVDLSfFLK`		non-susceptible form
`AVDLSaFLK`		non-susceptible form
`AVDaSHFLK`		non-susceptible form; susceptible form
`AfDLSfFLK`		non-susceptible form; susceptible form

Epitope Name AK9

Species (MHC/HLA) human

Variant Details

Showing all: 7 variant(s).

Variant ID.	`2504`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AlDLSHFLK`
Mutations	V/L
Epitope Location	V2L
HXB2 Location	V85L
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B, D
Variant Subtype	A1, B, D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AlDLSHFLK, was the autologous form for patients 2632 and 2840 who had a CTL response to this peptide. Patient 2275 did not have a CTL response to this variant.

Variant ID.	`2505`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AVDLgHFLK`
Mutations	S/G
Epitope Location	S5G
HXB2 Location	S88G
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B, D
Variant Subtype	A1, D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AVDLgHFLK elicited CTL response in patients 2632 and 2840. Patient 2275 did not have a CTL response to this variant.

Variant ID.	`2506`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AVDLaHFLK`
Mutations	S/A
Epitope Location	S5A
HXB2 Location	S88A
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B, D
Variant Subtype	A1, D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AVDLaHFLK, elicited CTL response in patients 2632 and 2840. Patient 2275 did not have a CTL response to this variant.

Variant ID.	`2508`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AVDLSfFLK`
Mutations	H/F
Epitope Location	H6F
HXB2 Location	H89F
Mutation Type	NSF: non-susceptible form
Epitope Subtype	A1, B, D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AVDLSfFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.

Variant ID.	`2510`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AVDLSaFLK`
Mutations	H/A
Epitope Location	H6A
HXB2 Location	H89A
Mutation Type	NSF: non-susceptible form
Epitope Subtype	A1, B, D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AVDLSaFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.

Variant ID.	`2511`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AVDaSHFLK`
Mutations	V/L
Epitope Location	V2L
HXB2 Location	V85L
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B, D
Variant Subtype	D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AVDaSHFLK, elicited a CTL response to this peptide in patient 2840 only. Patients 2632 and 2275 did not have a CTL response to this variant.

Variant ID.	`2512`
Epitope Seq.	`AVDLSHFLK`
Variant Seq.	`AfDLSfFLK`
Mutations	V/F H/F
Epitope Location	V2F H6F
HXB2 Location	V85F H89F
Mutation Type	NSF: non-susceptible form SF: susceptible form
Epitope Subtype	A1, B, D
Variant Subtype	D
Method	CD8 T-cell Elispot - IFNy
Note	AK9 variant, AfDLSfFLK, was the autologous form in patient 2275 in whom it was able to elicit CTL response. Patients 2632 and 2840 did not show any response to this variant.

References

Displaying record number 57496

HXB2 Location Nef(107-115) Nef Epitope Map
View variants at this location

Epitope

QEILDLWVY

Epitope Alignment

Variants

`QdILDLWVY`		susceptible form
`QEILDLWiY`		susceptible form
`QEILDaWVY`		susceptible form
`QEIaDLWVY`		susceptible form
`QEILDLWVh`		non-susceptible form
`QEILaLWVY`		non-susceptible form

Epitope Name QY9

Species (MHC/HLA) human

Variant Details

Showing all: 6 variant(s).

Variant ID.	`2493`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QdILDLWVY`
Mutations	E/D
Epitope Location	E2D
HXB2 Location	E108D
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QdILDLWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).

Variant ID.	`2494`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QEILDLWiY`
Mutations	V/I
Epitope Location	V8I
HXB2 Location	V114I
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QEILDLWiY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).

Variant ID.	`2495`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QEILDaWVY`
Mutations	L/A
Epitope Location	L6A
HXB2 Location	L112A
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QEILDaWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).

Variant ID.	`2496`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QEIaDLWVY`
Mutations	L/A
Epitope Location	L4A
HXB2 Location	L110A
Mutation Type	SF: susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QEIaDLWVY continued to elicit CTL response though at a low level in patient 2255 (Caucasian female, treated, autologous virus Clade B).

Variant ID.	`2513`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QEILDLWVh`
Mutations	Y/H
Epitope Location	Y9H
HXB2 Location	Y115H
Mutation Type	NSF: non-susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QEILDLWVh did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).

Variant ID.	`2514`
Epitope Seq.	`QEILDLWVY`
Variant Seq.	`QEILaLWVY`
Mutations	D/A
Epitope Location	D5A
HXB2 Location	D111A
Mutation Type	NSF: non-susceptible form
Epitope Subtype	B
Variant Subtype	B
Method	CD8 T-cell Elispot - IFNy
Note	Variant QEILaLWVY did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).